Use of proline specific endoproteases to hydrolyse peptides and proteins
The present invention relates to a process for the proteolytic hydrolysis of a peptide or a polypeptide, said peptide or polypeptide comprising 4 to 40, preferably 5 to 35, amino acid residues and said peptide or polypeptide is not hydrolysable by subtilisin whereby said peptide or polypeptide is hydrolysed by a proline specific endo protease at a pH of 6.5 or lower, preferably 5.5 or lower and more preferably 5.0 or lower to hydrolyse said peptide or polypeptide.
1. A method of using a proline specific endoprotease to hydrolyse at a pH of below 5.5, proline rich peptides which are brought with celiac disease, a disease associated with the occurrence of celiac disease, or a disease caused by a decreased level in a patient's body of proline specific proteases required for breakdown of these peptides, the method comprising administering a dietary supplement or a medicament comprised of said proline specific endoprotease for ingestion by a patient in need thereof, whereby the proline specific endoprotease is active in the stomach and is pepsin resistant.
2. A method of using a proline specific endoprotease having a pH optimum below 6.5, the method comprising administering said proline specific endoprotease for ingestion by a patient in need thereof, whereby the patient suffers from celiac disease, a disease associated with the occurrence of celiac disease, or a disease caused by a decreased level in the patient's body of proline specific proteases, and whereby the proline specific endoprotease is active in the stomach and is pepsin resistant.
3. The method according to claim 2 , wherein the proline specific endoprotease is an Aspergillus enzyme.
4. The method according to claim 1 , wherein the proline specific endoprotease is an Aspergillus enzyme.
5. The method according to claim 1 , wherein the proline specific endoprotease is an Aspergillus niger enzyme.
6. The method according to claim 2 , wherein the proline specific endoprotease is an Aspergillus niger enzyme.
7. The method according to claim 1 , wherein the patient suffers from celiac disease.
8. The method according to claim 2 , wherein the patient suffers from celiac disease.
9. The method according to claim 1 , wherein the patient is gluten sensitive.
10. The method according to claim 2 , wherein the patient is gluten sensitive.